CN104098553A - 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 - Google Patents
替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 Download PDFInfo
- Publication number
- CN104098553A CN104098553A CN201310383474.4A CN201310383474A CN104098553A CN 104098553 A CN104098553 A CN 104098553A CN 201310383474 A CN201310383474 A CN 201310383474A CN 104098553 A CN104098553 A CN 104098553A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- preparation
- ticagrelor
- compound shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCSc(nc1N[C@](CC2)[C@]3OC(C)(C)O[C@@]3[C@]2OCCO*)nc(Cl)c1NC(C(F)(F)F)=O Chemical compound CCCSc(nc1N[C@](CC2)[C@]3OC(C)(C)O[C@@]3[C@]2OCCO*)nc(Cl)c1NC(C(F)(F)F)=O 0.000 description 7
- CJJLJBFJNXMANZ-UHFFFAOYSA-N CCCSc(nc1Cl)nc(Cl)c1N Chemical compound CCCSc(nc1Cl)nc(Cl)c1N CJJLJBFJNXMANZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (21)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310383474.4A CN104098553B (zh) | 2013-04-10 | 2013-08-28 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
CN201710739212.5A CN107573333B (zh) | 2013-04-10 | 2013-08-28 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
PCT/CN2014/073388 WO2014166324A1 (zh) | 2013-04-10 | 2014-03-13 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
EP14782391.8A EP2985286B1 (en) | 2013-04-10 | 2014-03-13 | Midbody of ticagrelor and preparation method therefor, and preparation method for ticagrelor |
JP2016506761A JP6332818B2 (ja) | 2013-04-10 | 2014-03-13 | チカグレロルの中間体およびその製造法、およびチカグレロルの製造法 |
US14/781,803 US9359366B2 (en) | 2013-04-10 | 2014-03-13 | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor |
TW103110842A TWI634116B (zh) | 2013-04-10 | 2014-03-24 | 替格瑞洛的中間體及其製備方法和替格瑞洛的製備方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310122613.8 | 2013-04-10 | ||
CN2013101226138 | 2013-04-10 | ||
CN201310122613 | 2013-04-10 | ||
CN201310383474.4A CN104098553B (zh) | 2013-04-10 | 2013-08-28 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710739212.5A Division CN107573333B (zh) | 2013-04-10 | 2013-08-28 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104098553A true CN104098553A (zh) | 2014-10-15 |
CN104098553B CN104098553B (zh) | 2017-11-28 |
Family
ID=51667139
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710739212.5A Active CN107573333B (zh) | 2013-04-10 | 2013-08-28 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
CN201310383474.4A Active CN104098553B (zh) | 2013-04-10 | 2013-08-28 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710739212.5A Active CN107573333B (zh) | 2013-04-10 | 2013-08-28 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9359366B2 (zh) |
EP (1) | EP2985286B1 (zh) |
JP (1) | JP6332818B2 (zh) |
CN (2) | CN107573333B (zh) |
HK (1) | HK1202533A1 (zh) |
TW (1) | TWI634116B (zh) |
WO (1) | WO2014166324A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105669681A (zh) * | 2016-04-11 | 2016-06-15 | 成都华宇制药有限公司 | 一种替格瑞洛的合成方法 |
CN105801583A (zh) * | 2014-12-31 | 2016-07-27 | 徐州万邦金桥制药有限公司 | 一种替格瑞洛的纯化方法 |
CN105859720A (zh) * | 2015-01-20 | 2016-08-17 | 上海方楠生物科技有限公司 | 一种替格瑞洛溶液的制备方法 |
CN105940003A (zh) * | 2013-11-08 | 2016-09-14 | 赞蒂瓦有限合伙公司 | 替格瑞洛合成中间物的制备方法和新颖结晶形式 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
CN111848632A (zh) * | 2020-09-07 | 2020-10-30 | 河南师范大学 | 一种血小板聚集抑制剂替格瑞洛的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999005143A1 (en) * | 1997-07-22 | 1999-02-04 | Astra Pharmaceuticals Ltd. | Novel compounds |
CN1128801C (zh) * | 1998-12-04 | 2003-11-26 | 阿斯特拉曾尼卡有限公司 | 新的三唑并(4,5-d)嘧啶化合物 |
CN102149716A (zh) * | 2008-09-09 | 2011-08-10 | 阿斯利康(瑞典)有限公司 | 制备[1S-[1α,2α,3β(1S*,2R*),5β]]-3-[7-[2-(3,4-二氟苯基)-环丙氨基]-5-(丙硫基)-3H-1,2,3-三唑并[4,5-d]嘧啶-3-基]-5-(2-羟乙氧基)环戊烷-1,2-二醇的方法及其中间体 |
CN102675321A (zh) * | 2012-05-11 | 2012-09-19 | 上海皓元化学科技有限公司 | 一种替卡格雷的制备方法 |
WO2012138981A2 (en) * | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
CN102875537A (zh) * | 2012-09-10 | 2013-01-16 | 常州制药厂有限公司 | 一种新的抗血栓药物的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577558A2 (de) * | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
JP3398152B2 (ja) * | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体 |
GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
GB0013488D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
CN101148450A (zh) * | 2007-11-02 | 2008-03-26 | 严红芳 | 一种核苷化合物的制备方法 |
EP3135675A1 (en) | 2009-07-27 | 2017-03-01 | Auspex Pharmaceuticals, Inc. | Deuterated derivatives of ticagrelor for medical use |
MX2013007115A (es) * | 2010-12-20 | 2014-02-10 | Actavis Group Ptc Ehf | Procesos novedosos para preparar derivados de triazolo[4, 5 - d] pirimidina e intermediarios de los mismos. |
IN2014KN01062A (zh) * | 2011-10-27 | 2015-10-09 | Lek Pharmaceuticals | |
CA2859580A1 (en) * | 2011-12-23 | 2013-06-27 | Lek Pharmaceuticals D.D. | Synthesis of triazolopyrimidine compounds |
EP2834247A4 (en) * | 2012-04-05 | 2016-03-30 | Reddys Lab Ltd Dr | PREPARATION OF TICAGRELOR |
CN102659815B (zh) | 2012-05-04 | 2013-07-17 | 开原亨泰制药股份有限公司 | 一种制备选择性抗凝血药替卡格雷及其中间体的方法 |
-
2013
- 2013-08-28 CN CN201710739212.5A patent/CN107573333B/zh active Active
- 2013-08-28 CN CN201310383474.4A patent/CN104098553B/zh active Active
-
2014
- 2014-03-13 WO PCT/CN2014/073388 patent/WO2014166324A1/zh active Application Filing
- 2014-03-13 JP JP2016506761A patent/JP6332818B2/ja not_active Expired - Fee Related
- 2014-03-13 EP EP14782391.8A patent/EP2985286B1/en not_active Not-in-force
- 2014-03-13 US US14/781,803 patent/US9359366B2/en active Active
- 2014-03-24 TW TW103110842A patent/TWI634116B/zh not_active IP Right Cessation
-
2015
- 2015-03-24 HK HK15102985.6A patent/HK1202533A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999005143A1 (en) * | 1997-07-22 | 1999-02-04 | Astra Pharmaceuticals Ltd. | Novel compounds |
CN1128801C (zh) * | 1998-12-04 | 2003-11-26 | 阿斯特拉曾尼卡有限公司 | 新的三唑并(4,5-d)嘧啶化合物 |
CN102149716A (zh) * | 2008-09-09 | 2011-08-10 | 阿斯利康(瑞典)有限公司 | 制备[1S-[1α,2α,3β(1S*,2R*),5β]]-3-[7-[2-(3,4-二氟苯基)-环丙氨基]-5-(丙硫基)-3H-1,2,3-三唑并[4,5-d]嘧啶-3-基]-5-(2-羟乙氧基)环戊烷-1,2-二醇的方法及其中间体 |
WO2012138981A2 (en) * | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
CN102675321A (zh) * | 2012-05-11 | 2012-09-19 | 上海皓元化学科技有限公司 | 一种替卡格雷的制备方法 |
CN102875537A (zh) * | 2012-09-10 | 2013-01-16 | 常州制药厂有限公司 | 一种新的抗血栓药物的制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105940003A (zh) * | 2013-11-08 | 2016-09-14 | 赞蒂瓦有限合伙公司 | 替格瑞洛合成中间物的制备方法和新颖结晶形式 |
CN105801583A (zh) * | 2014-12-31 | 2016-07-27 | 徐州万邦金桥制药有限公司 | 一种替格瑞洛的纯化方法 |
CN105859720A (zh) * | 2015-01-20 | 2016-08-17 | 上海方楠生物科技有限公司 | 一种替格瑞洛溶液的制备方法 |
CN105669681A (zh) * | 2016-04-11 | 2016-06-15 | 成都华宇制药有限公司 | 一种替格瑞洛的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
US20160052928A1 (en) | 2016-02-25 |
EP2985286B1 (en) | 2017-10-11 |
WO2014166324A1 (zh) | 2014-10-16 |
CN107573333B (zh) | 2019-10-18 |
JP2016515635A (ja) | 2016-05-30 |
CN104098553B (zh) | 2017-11-28 |
EP2985286A4 (en) | 2016-09-14 |
TWI634116B (zh) | 2018-09-01 |
JP6332818B2 (ja) | 2018-05-30 |
HK1202533A1 (zh) | 2015-10-02 |
EP2985286A1 (en) | 2016-02-17 |
TW201439087A (zh) | 2014-10-16 |
US9359366B2 (en) | 2016-06-07 |
CN107573333A (zh) | 2018-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104098553A (zh) | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 | |
CN108047261B (zh) | 一种克立硼罗的制备方法 | |
CN104356112A (zh) | 一种色瑞替尼的制备方法 | |
WO2002038569A1 (en) | Imidazo-pyrimidine derivatives as ligands for gaba receptors | |
CN106083745A (zh) | 6‑氟‑3‑羟基‑2‑吡嗪酰胺的合成方法 | |
CN106928236A (zh) | 一种瑞博西尼的合成工艺 | |
CN103351372A (zh) | 替卡格雷中间体的制备方法 | |
CN103897028A (zh) | 一种硼替佐米的合成方法 | |
CN103664952A (zh) | 一种佐匹克隆的制备方法 | |
CN113896732B (zh) | 抗癌药物卡马替尼的制备方法及其应用 | |
CN102633802B (zh) | 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法 | |
CN104592222B (zh) | 抗血小板药物azd6482的制备方法 | |
Layek et al. | A highly effective synthesis of 2-alkynyl-7-azaindoles: Pd/C-mediated alkynylation of heteroaryl halides in water | |
Wang et al. | An efficient synthesis of benzo [b] benzofurano [2, 3-e]-[1, 6] naphthyridine-8-ones | |
CN104031071A (zh) | 一种氯诺昔康及中间体的制备方法 | |
CN103044330B (zh) | 西地那非中间体4-氨基-1-甲基-3-正丙基吡唑-5-甲酰胺的绿色合成新工艺 | |
CN101880285B (zh) | 一种烯丙基取代喜树碱化合物的合成方法 | |
CN101891689B (zh) | 盐酸γ-羟基苯达莫司汀的制备方法 | |
CN102786553B (zh) | 一种葡萄糖醛酸苷类化合物的纯化方法 | |
AU2008351926A1 (en) | Derivatives of N-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | |
CN105085356A (zh) | 小构树碱类化合物及其制备方法和应用 | |
CN104860881A (zh) | 8-(硝基甲基)喹啉类化合物和8-甲氨基四氢喹啉类化合物的合成方法 | |
CN105085357A (zh) | 小构树碱类化合物及其制备方法和应用 | |
CN103788084A (zh) | 四氢异喹啉衍生物及其合成方法 | |
CN102491972B (zh) | 一种咔唑衍生物及其制备方法和作为抗癌药物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Huang Jinkun Inventor after: Sun Shaoguang Inventor after: Song Defu Inventor after: He Biao Inventor after: Lai Xiaobo Inventor before: Sun Shaoguang Inventor before: Song Defu Inventor before: He Biao Inventor before: Lai Xiaobo |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SUN SHAOGUANG SONG DEFU HE BIAO LAI XIAOBO TO: HUANG JINKUN SUN SHAOGUANG SONG DEFU HE BIAO LAI XIAOBO |
|
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1202533 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1202533 Country of ref document: HK |